JP2017523187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523187A5 JP2017523187A5 JP2017504713A JP2017504713A JP2017523187A5 JP 2017523187 A5 JP2017523187 A5 JP 2017523187A5 JP 2017504713 A JP2017504713 A JP 2017504713A JP 2017504713 A JP2017504713 A JP 2017504713A JP 2017523187 A5 JP2017523187 A5 JP 2017523187A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- complex
- administered
- subject
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462030394P | 2014-07-29 | 2014-07-29 | |
| US62/030,394 | 2014-07-29 | ||
| PCT/US2015/042489 WO2016018920A1 (en) | 2014-07-29 | 2015-07-28 | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523187A JP2017523187A (ja) | 2017-08-17 |
| JP2017523187A5 true JP2017523187A5 (enExample) | 2018-08-30 |
| JP6655061B2 JP6655061B2 (ja) | 2020-02-26 |
Family
ID=55218246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504713A Active JP6655061B2 (ja) | 2014-07-29 | 2015-07-28 | 状態を治療するためのｉｌ−１５およびｉｌ−１５ｒアルファヘテロ二量体用量増加レジメン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10335460B2 (enExample) |
| EP (1) | EP3174974B1 (enExample) |
| JP (1) | JP6655061B2 (enExample) |
| ES (1) | ES2811974T3 (enExample) |
| WO (1) | WO2016018920A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5603012B2 (ja) | 2005-12-02 | 2014-10-08 | トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ | 非天然表面タンパク質を提示するキメラウイルス及びその使用 |
| PE20151921A1 (es) | 2013-03-14 | 2015-12-26 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| AU2015222685A1 (en) | 2014-02-27 | 2016-09-08 | Viralytics Limited | Combination method for treatment of cancer |
| US20190117690A1 (en) | 2016-04-06 | 2019-04-25 | The University State Of America As Represented By The Secretary Of The Department Of Health And Hum | Use of heterodimeric il-15 in adoptive cell transfer |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CA3024509A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| EP3464352B1 (en) * | 2016-05-27 | 2021-03-24 | Altor BioScience Corporation | Construction and characterization of multimeric il-15-based molecules with cd3 binding domains |
| JP7599819B2 (ja) * | 2016-06-02 | 2024-12-16 | イムノコア リミテッド | ｇｐ１００特異的ＴＣＲ－抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| WO2018013855A2 (en) | 2016-07-14 | 2018-01-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines |
| CA3049652A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| US20200237874A1 (en) * | 2017-01-20 | 2020-07-30 | Novartis Ag | Combination therapy for the treatment of cancer |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CA3064375A1 (en) | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| AU2019213843A1 (en) * | 2018-02-02 | 2020-08-20 | Aduro Biotech Inc. | Combination of STING agonist and IL-15/IL15-Ra for the treatment of cancer |
| WO2019204646A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
| MX2020014290A (es) | 2018-06-22 | 2021-08-05 | Cugene Inc | Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. |
| CN121086085A (zh) | 2018-06-22 | 2025-12-09 | 科优基因公司 | 新型白介素-15 (il-15)融合蛋白及其用途 |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| US20210386788A1 (en) * | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12624086B2 (en) | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| US12497435B2 (en) * | 2019-01-11 | 2025-12-16 | Memorial Sloan Kettering Cancer Center | Multimerization of IL-15/IL-15R-alpha-fc complexes to enhance immunotherapy |
| SG11202111409YA (en) | 2019-05-20 | 2021-12-30 | Cytune Pharma | IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| AU2020403148A1 (en) * | 2019-12-13 | 2022-06-30 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| AU2021260989A1 (en) * | 2020-04-22 | 2022-11-17 | Novartis Ag | Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetIL-15) |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| US20260048099A1 (en) | 2022-08-16 | 2026-02-19 | The United States Of America, As Represented By The Secretary, Deparment Of Health And Human Service | Synergistic interactions for improved cancer treatment |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2025085672A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| WO2025184249A1 (en) * | 2024-02-28 | 2025-09-04 | Emory University | Cytokine therapies for managing hiv and other viral infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| DE4135070C1 (enExample) | 1991-10-24 | 1993-05-19 | Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De | |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5591630A (en) | 1994-05-06 | 1997-01-07 | Immunex Corporation | Monoclonal antibodies that bind interleukin-15 receptors |
| US6569681B1 (en) | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
| US20030044406A1 (en) | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| ES2367027T3 (es) | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
| WO2007001677A2 (en) * | 2005-05-17 | 2007-01-04 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| WO2007070488A2 (en) | 2005-12-12 | 2007-06-21 | The Cbr Institute For Biomedical Research, Inc. | Integrin alpha l i domain mutants with increased binding affinity |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| EP2388266B1 (en) | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| CA2727953C (en) | 2008-08-22 | 2017-05-16 | Magna Seating Inc. | Disc recliner with reduced backlash |
| WO2011020047A1 (en) * | 2009-08-14 | 2011-02-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| US20150359853A1 (en) * | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
-
2015
- 2015-07-28 US US15/328,882 patent/US10335460B2/en active Active
- 2015-07-28 JP JP2017504713A patent/JP6655061B2/ja active Active
- 2015-07-28 EP EP15828027.1A patent/EP3174974B1/en active Active
- 2015-07-28 WO PCT/US2015/042489 patent/WO2016018920A1/en not_active Ceased
- 2015-07-28 ES ES15828027T patent/ES2811974T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kozuch et al. | Treatment of inflammatory bowel disease: a review of medical therapy | |
| JP5320301B2 (ja) | 感染症の処置のためのｉｌ−２３アンタゴニストの使用 | |
| Gyires et al. | Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities | |
| Stallmach et al. | An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo | |
| JP2014515763A5 (enExample) | ||
| RU2676333C2 (ru) | Способы снижения частоты приступов астмы с применением бенрализумаба | |
| Martin | Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis | |
| RU2016122957A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
| JP2013508392A5 (enExample) | ||
| JP2016527286A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| US20080008716A1 (en) | Combined Pharmaceutical Composition Comprising an Anti-4-1BB Monoclonal Antibody and Chemotherapeutic Anti-Cancer Agent for Preventing and Treating Cancer Disease | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2013543501A5 (enExample) | ||
| JP2023540795A5 (enExample) | ||
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| JP2022188083A5 (enExample) | ||
| Kochetkova et al. | Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27 | |
| JP2015500822A5 (enExample) | ||
| JP2024540275A5 (enExample) | ||
| US20200377596A1 (en) | Dosing of bispecific t cell engager | |
| JP2019519584A5 (enExample) | ||
| Argollo et al. | Interleukin-23 blockers: born to be first-line biologic agents in inflammatory bowel disease? | |
| Danese et al. | Biological Therapies for Inflammatory Bowel Disease: Research DrivesClinics | |
| Danese et al. | Biological agents for ulcerative colitis: hypes and hopes |